Becton Dickinson Vitals Drop: Analysts ‘Have Been Wrong’ On This Med Tech Stock For Years

Becton Dickinson receives multiple downgrades as analysts cite weakening organic growth and trimmed price targets following a Q2 update.

Latest Ratings for BDX

Date Firm Action From To
Feb 2022 Morgan Stanley Maintains Overweight
Feb 2022 SVB Leerink Maintains Market Perform
Jan 2022 Morgan Stanley Maintains Overweight

View More Analyst Ratings for BDX

View the Latest Analyst Ratings

read more

Leave a Reply

Your email address will not be published. Required fields are marked *